Collegium Pharmaceutical
Stoughton
About Collegium Pharmaceutical
Collegium Pharmaceutical is a specialty pharmaceutical company focused on the development of proprietary, late-stage pharmaceutical products. These products address the growing problems associated with non-medical use and abuse of prescription drugs through formulation based improvements protected by intellectual property (IP). Collegium is focused on building a portfolio of products for the treatment of chronic pain that possess tamper-resistant features and provide extended-release delivery using its patent-protected DETERx formulation platform.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 251 – 500
- Estimated revenue: $500K – $1M
- Total funding: $1.3B
- Funding stage: IPO
- Last round: Post-IPO Debt (Dec 2025)
- Ticker: nasdaq:COLL
- Website: collegiumpharma.com
- Phone: (781) 713-3699
Industries & Categories
Biotechnology, Life Science, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/collegium-pharmaceutical-76144 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.